Protonix Treatment of Maintenance of Healing in Pediatric Participants Aged 1-11 Years and 12-17 Years
Phase 2
Not yet recruiting
- Conditions
- Other esophagitis,
- Registration Number
- CTRI/2024/04/065083
- Lead Sponsor
- Pfizer Inc.,
- Brief Summary
The purpose of this study is to explore the outcomes, tolerability and safety of 2 different doses of oral pantoprazole (full healing dose, half healing dose), assigned based upon weight, for the maintenance of healing of erosive esophagitis in pediatric participants aged 1 to 17 years with endoscopically-confirmed, healed erosive esophagitis.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Not Yet Recruiting
- Sex
- All
- Target Recruitment
- 126
Inclusion Criteria
- (1) Participants must have a documented erosive lesion with an Los Angeles (LA) Grade of A to D prior to starting Proton Pump Inhibitor treatment (2) Capable of giving signed informed consent or assent (3) Willingness and ability of the participant or parent or legal guardian to complete the eDiary (4) Willing and able to comply with all scheduled visits, treatment plan, laboratory tests, lifestyle considerations, and other study procedures, including the use of the eDiary.
- (5) Male and female participants aged 1 to 17 years.
- (6) Minimum body weight 7 kilogram and weight at least at the 5th percentile per the Center for Disease Control standard age and weight chart, for the participants age.
- (7) To be considered a female of non childbearing potential, the participant must meet at least 1 of the following criteria (8) Premenarchal-The investigator (or other appropriate staff) must discuss the participants premenarchal status with the participant and parent or legal guardian at office visits and during telephone contacts, as participants who achieve menarche during the study would no longer be considered female participants of non childbearing potential and must comply with the protocol requirements applicable to women of childbearing potential.
Exclusion Criteria
- (1) Previous administration of an investigational drug or vaccine within 30 days (or as determined by the local requirement) or 5 half-lives preceding the first dose of study intervention used in this study (whichever is longer).
- (2) Children that may be at high risk from procedural sedation should be carefully evaluated.
- Participants with a history of complications during prior procedural sedation (3) History or presence of upper gastrointestinal anatomic or motor disorders (4) Family history of malignant hyperthermia (5) Known hypersensitivity to any Proton Pump Inhibitor, including pantoprazole or to any substituted benzimidazole or to any of the excipients.
- (6) Any disorder requiring chronic (daily) use of warfarin, heparin, other anticoagulants, methotrexate, atazanavir or nelfinavir, clopidogrel, or potent inhibitors or inducers of CYP2C19 (eg, phenytoin, sulfamethoxazole, valproic acid, carbamazepine, and griseofulvin).
- (7) Serum creatine kinase levels greater than 3 x upper limit of normal.
- (8) Known history of human immunodeficiency virus or clinical manifestations of acquired immune deficiency syndrome.
- (9) Active malignancy of any type, or history of a malignancy.
- Participants with a history of malignancies that have been surgically removed or eradicated by irradiation or chemotherapy and who have no evidence of recurrence for at least 5 years before Screening are acceptable.
- (10) Diagnosed as having or has received treatment for esophageal, gastric, pyloric channel, or duodenal ulceration within 30 days before the Screening visit.
- (11) Alanine aminotransferase or blood urea nitrogen greater than 2.0 upper limit of normal or estimated creatinine greater than 1.5 X upper limit of normal for age or any other laboratory abnormality considered by the Investigator to be clinically significant within 14 days before the Baseline Visit (Day 1).
- (12) Other acute or chronic medical or psychiatric condition including recent (within the past year) or active suicidal ideation or behavior or laboratory abnormality that may increase the risk associated with study participation or study intervention administration or may interfere with the interpretation of study results and, in the judgment of the investigator, would make the participant inappropriate for entry into this study.
- (13) Has, in the Investigators opinion, a serious chronic condition (eg, diabetes, epilepsy), which is either not stable or not well controlled and may interfere with the conduct of the study.
- (14) Has any condition possibly affecting drug absorption (eg, gastrectomy).
- (15) Prior or Concomitant Therapy: (i) Frequent, repeated use of oral or parenteral glucocorticoids (eg, prednisone, prednisolone, dexamethasone).
- Steroid inhalers and topical steroids may be used.
- (ii) Pregnant female participants; breastfeeding female participants.
- (iii) Is unwilling or unable to comply with the Lifestyle Considerations section.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Proportion of patients with endoscopically confirmed maintenance of healing of erosive esophagitis at Week 24, considering patients with excessive use of rescue medication as treatment failures Week 24
- Secondary Outcome Measures
Name Time Method Number of Participants With Change From Baseline in Physical Examinations & Vital Signs Baseline up to 36 weeks Incidence of Adverse Events (AEs) Baseline up to 36 weeks Number of Participants With Change From Baseline in Laboratory Tests Results Baseline up to 36 weeks
Trial Locations
- Locations (5)
Gujarat Hospital Gastro and Vascular Centre
🇮🇳Surat, GUJARAT, India
Medical College and Hospital
🇮🇳Kolkata, WEST BENGAL, India
Oriion Citicare Hospital-Institutional Ethics Committee Oriion Citicare Super Speciality Hospital
🇮🇳Aurangabad, MAHARASHTRA, India
S R Kalla Memorial Gastro and General Hospital
🇮🇳Jaipur, RAJASTHAN, India
Yashoda Hospitals
🇮🇳Hyderabad, TELANGANA, India
Gujarat Hospital Gastro and Vascular Centre🇮🇳Surat, GUJARAT, IndiaDr Saumin Prakashbhai ShahPrincipal investigator919408042224dr.sauminpshah@gmail.com